Loading
A phase 2/3 trial testing HS-20117 in non-small-cell lung cancer, now recruiting.
A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer is a phase 2/3 interventional study registered as NCT06417008, led by Hansoh BioMedical R&D, and recruiting on the registry. Official title: A Phase Ib/III Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Immunogenicity of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer. Planned enrolment is 1080 participants (estimated). The study started in 2024-05-28 and primary completion is expected in 2026-06-01. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/